Loading clinical trials...
Loading clinical trials...
The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Department of Infectious Diseases, Aalborg Hospital
Aalborg, Denmark
Department of Infectious Diseases, Skejby Hospital
Aarhus, Denmark
Start Date
March 1, 2007
Last Updated
November 1, 2007
80
ESTIMATED participants
Twinrix
BIOLOGICAL
interleukin-2
BIOLOGICAL
Lead Sponsor
Aalborg University Hospital
NCT07024641
NCT06694805
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04142047